| Literature DB >> 35726030 |
Bijoya Sen1,2, Savera Aggarwal1, Rhisita Nath1, Rashi Sehgal1, Ravinder Singh1, Khushboo Agrawal1, Ashwini Nagaraghatta Shashidhara3, Archana Rastogi3, Meenu Bajpai4, Viniyendra Pamecha5, Nirupma Trehanpati1, Gayatri Ramakrishna6.
Abstract
Presence of dysfunctional senescent hepatocytes is a hallmark feature of liver cirrhosis which finally culminates in liver cancer. We now report the presence of senescent hepatocytes (p21 and p53 positive) in the vicinity of infiltrated immune cells in hepatocellular carcinoma tissue specimens by immunohistochemistry. Hence, we evaluated in vitro, the relevance of senescent hepatoma cells in altering the fate of monocytes and neutrophils by assaying for macrophage polarization and extracellular trap (NETs) formation, respectively. Premature senescence was induced in hepatoma cells (HepG2 and Huh7 cells) by treating cells with doxorubicin. Senescent hepatoma cells showed strong inflammatory phenotype with induced expression of cytokines (IL1β, IL6, IL8 and IL13) as evaluated by flow cytometry. The senescent secretome from hepatoma cells when incubated with healthy monocytes caused it to differentiate predominantly towards M2 fate (CD80low CD86low CD163high CD206high) when analysed by flow cytometry. This was corroborated by the finding in clinical samples where human hepatocellular carcinoma harbouring senescent hepatocytes showed presence of M2 macrophages, while M1 macrophages were predominant in non-tumorous region. Additionally, the senescent secretome from Huh7 cells enhanced the NETs formation, while HepG2 secretome had an inhibitory effect. In conclusion, the "pro-inflammatory" senescent secretome drives non-inflammatory type M2 macrophage polarization and modulated neutrophil traps which in turn can influence the tumor microenvironment.Entities:
Keywords: And inflammasome; Hepatocellular carcinoma (HCC); Macrophage polarization; Neutrophil extracellular traps (NETs); Senescence; Senescence-associated secretory phenotype (SASP)
Mesh:
Year: 2022 PMID: 35726030 DOI: 10.1007/s12032-022-01732-w
Source DB: PubMed Journal: Med Oncol ISSN: 1357-0560 Impact factor: 3.064